Main Menu

The Post Clinical Research Support Office Updates for December 2023

Clinical Research Support Office Updates for December 2023

UPDATE – Epic Fee Schedule for Clinical Research Hospital Charges ONLY | The Revenue Cycle Support Services (RCSS) current Research Pricing Methodology for Federal and Commercial charges will be changed to a discount percentage rate: Federal 31% and Commercial 41%. This will go into effect on Jan 1, 2024.  All net new trials that have an IRB Initial Approval Date of Jan 1st, 2024, will receive the new Epic pricing. For studies that have a final budget prior to Jan 1st, 2024, will remain on the existing Epic Fee Schedule and will be grandfathered in.  For trials currently under negotiation prior to Jan 1st, 2024, will be grandfathered in, we do ask that you send a list of these studies to Clinical Research Support Office (CRSO) Finance team.  A new version of the Research Pricing Methodology will be published soon by the RCSS office.  This will be hosted on the CRSO website.  

W9 Collection for Participant Payment | Accounts Payable Office and Tax Services have asked that we submit W9s for all participants that have received a compensation greater than $100. The CRSO office has reached out to several departments, and we appreciate everyone’s help. We are sending this reminder to please add those missing W9s to OnCore or email the CRSO Finance a copy of the W9s. There are only 3 weeks left before the end of the calendar year.   

Unclaimed Payments | Grants & Contracts Accounting (GCA) have asked that study teams please submit Remittance Advice to Alex Sotelo. She has been able to match these to payments that have not been claimed by study teams. GCA wants to make sure study teams are paid for their research.